Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study to Evaluate the Safety and Tolerability of AB122 in Subjects with Advanced Solid Tumors

Trial Profile

A Phase 1 Study to Evaluate the Safety and Tolerability of AB122 in Subjects with Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AB 122 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Arcus Biosciences
  • Most Recent Events

    • 09 May 2018 According to an Arcus Biosciences media release, dosing initiated in a third cohort and company expect to present safety, pharmacokinetic, receptor occupancy and clinical activity data in the second half of 2018.
    • 20 Nov 2017 New trial record
    • 13 Nov 2017 According to an Arcus Biosciences media release, the company initiated this trial in November and data is anticipated in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top